Ionis Pharmaceuticals Inc
F:ISI
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
22.73
71.68
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
|
Ionis Pharmaceuticals Inc
NASDAQ:IONS
|
12.3B USD |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
378.8B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
177.8B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
155.1B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
112.1B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
77.2B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
85.7B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
41.2B EUR |
Loading...
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
47.3B USD |
Loading...
|
Market Distribution
| Min | -4 418 600% |
| 30th Percentile | -9.6% |
| Median | 3.1% |
| 70th Percentile | 11.3% |
| Max | 1 135 400% |
Other Profitability Ratios
Ionis Pharmaceuticals Inc
Glance View
In the realm of pharmaceutical innovation, Ionis Pharmaceuticals Inc. has carved a niche defined by its pioneering efforts in antisense technology. Founded in 1989, Ionis stands as a trailblazer in the development of RNA-targeted therapies, which deviate from the traditional drug development pathways by focusing on genetic solutions. The company specializes in antisense oligonucleotides—short, synthetic strands of DNA or RNA designed to bind selectively to specific messenger RNA (mRNA). By doing so, they aim to modulate the expression of genes associated with various diseases. This unique approach allows Ionis to address ailments at the genetic level, potentially preventing the production of disease-causing proteins, thus offering alternative therapeutic options for serious diseases. Ionis Pharmaceuticals monetizes its scientific breakthroughs through a diverse revenue stream model. It engages in multiple collaborative partnerships with major pharmaceutical companies, such as Biogen and AstraZeneca, which provide upfront payments, milestone-based fees, and royalties on lucrative antisense drugs that emerge from these alliances. Furthermore, Ionis holds an extensive internal pipeline, advancing proprietary drugs through various stages of research and clinical trials. By strategically balancing in-house projects with external collaborations, Ionis capitalizes on its innovative platform while mitigating financial risks. This dual-strategy not only sustains the company financially but positions it at the forefront of personalized medicine, potentially revolutionizing the landscape of therapeutic development.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Ionis Pharmaceuticals Inc is -26.5%, which is above its 3-year median of -49%.
Over the last 3 years, Ionis Pharmaceuticals Inc’s Net Margin has decreased from 0.8% to -26.5%. During this period, it reached a low of -66.6% on Sep 30, 2023 and a high of 0.8% on Aug 30, 2022.